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Amyotrophic lateral sclerosis (ALS) is a fatal neurological disease characterized by the degeneration of motor
neurons. Currently, there is no effective therapy for ALS. Stem cell transplantation is a potential therapeutic
strategy forALS,and the reprogrammingofadult somaticcells into inducedpluripotentstemcells (iPSCs) repre-
sents a novel cell source. In this study, we isolated a specific neural stem cell (NSC) population from human
iPSCs based on high aldehyde dehydrogenase activity, low side scatter and integrin VLA4 positivity.
Weassessed the therapeuticeffectsof theseNSCson thephenotypeofALSmiceafter intrathecalor intravenous
injections. Transplanted NSCsmigrated and engrafted into the central nervous system via both routes of injec-
tion. Comparedwith control ALS, treated ALSmice exhibited improved neuromuscular function andmotor unit
pathology and significantly increased life span, in particular with the systemic administration of NSCs (15%).
These positive effects are linked to multiple mechanisms, including production of neurotrophic factors and re-
duction ofmicro- andmacrogliosis. NSCs induced a decrease in astrocyte number through the activation of the
vanilloid receptor TRPV1. We conclude that minimally invasive injections of iPSC-derived NSCs can exert a
therapeutic effect in ALS. This study contributes to advancements in iPSC-mediated approaches for treating
ALS and other neurodegenerative diseases.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative
disease that is characterized by clinical and pathological
signs of upper and lower motor neuron degeneration, progres-
sive paralysis and precocious death (1). Currently, there are no
effective treatments. The majority of cases are sporadic, and
10% are familial (1). Of the familial cases, 20% are
linked to mutations in the superoxide dismutase 1 (SOD1)
gene (2). Although several other causative genes have been
identified in recent years, with C9ORF72 and TARDBP
among the most common, almost 50% of familial ALS cases
have unidentified genetic aetiology, although this proportion
may vary according to different genetic backgrounds (1). The
aethiopathogenesis of sporadic ALS is largely unknown (3),
which hinders the development of clinically meaningful treat-
ment (1,4,5).
Expression ofmutant SOD1 in rodents causes progressive de-
generation of motor neurons, leading to progressive paralysis
that resembles themanifestations of humanALS (6,7).Although
the molecular mechanisms leading to progressive neuronal
degeneration are likely multi-factorial, increasing evidence
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implies a role for non-autonomous cell death as a key event in the
disease pathology (3). In particular, environmental non-
neuronal cells such as astrocytes and microglia are involved in
the death of motor neurons (8).
Cell transplantation therapy could be a promising therapeutic
strategy for a number of disease processes. There is accumulat-
ing experimental evidence of non-cell-autonomous contribu-
tions of cells other than motor neurons to ALS pathology. In
addition, the disease is characterized by a complex interplay of
several pathogenic events, such as protein aggregation, glutam-
ate toxicity, RNA dysfunction and inflammatory events. Stem
cell transplantation can be therapeutic viamultiplemechanisms,
including replacement of micro-environmental cells such as
astrocytes and neuronal precursors. Furthermore, stem cell
therapy can reduce inflammation and neuropathological hall-
marks such as neuronal tangles/aggregates, protect motor
neurons and neuronal circuitry and ultimately replace degener-
ated cells (9).
Our group andothers have demonstrated these positive effects
of stemcell transplantation (neural andnon-neural cells) (9–15).
In 2009, theUSFood andDrugAdministration approved thefirst
phase I safety trial of direct intraspinal transplantation of neural
stemcells (NSCs) into patientswithALS; the study is still in pro-
gress (9). Recently, transplanted NSCswere demonstrated to ef-
fectively slow the disease and prolong survival inALSmice, and
in some cases (25% of treated mice), the phenotype was com-
pletely rescued (survival increased to over a full year versus
4months in untreated animals) (10). These data represent an un-
precedented therapeutic success inmotor neuron diseasemodels
compared with other pharmacological/molecular treatments.
However, 40% of mice injected with NSCs show a very mild in-
crease in survival. The reason for this variability is unknown and
maybe related to the typeof cell transplanted andour incomplete
understanding of the key variables important for therapeutic
success. Human NSCs are derived from primary central
nervous system (CNS) tissue (fetal brain), which is a limited
source of cells. Furthermore, multiple direct injections of stem
cells into the spinal cord will require major invasive surgery if
this strategy is translated to humans.
Themethodof cell delivery represents amajor hurdle indevel-
oping a cell-mediated approach. The cells must be distributed
along the CNS, targeting both lower and upper motor neurons,
using a non-invasivemethod that leads to sufficient engraftment.
Themethod presented here progresses beyond the current limits
of cell therapy, which is based on direct injection into the spinal
cord.Weutilize a cell population that can efficientlymigrate into
the CNS from the cerebrospinal fluid (CSF) or from the blood
after systemic injection. We previously described that the selec-
tion of a specific subset of NSCs can provide a major advantage
in therapeutic efficacy with respect to mixed NSC/neuronal pre-
cursor populations (11–13). We previously demonstrated posi-
tive therapeutic effects of a subset of self-renewing, multipotent
rodentNSCs selected for their aldehydedehydrogenase (ALDH)
activity. When intrathecally transplanted into the SMA and
SMARD1 mouse models of motor neuron disease, the cells
migrate into the spinal cord and ameliorate the disease
phenotype (11,13).
In this work, we sought to test the therapeutic potential of
human NSCs that were selected for their high ALDH activity,
low orthogonal light scattering (ALDHhiSSClo) and expression
of integrinVLA4.ThepresenceofVLA4 inNSCsallows them to
cross the blood-brain barrier (BBB), particularly in the presence
of inflammation or a weakened BBB, as in ALS animal models
and human patients (16,17).
In addition, we wanted to explore minimally invasive admin-
istration protocols, such as intrathecal and systemic intravenous
transplantation, in an ALS mouse model. This strategy allowed
us to repeatedly deliver the cells, achieving a widespread distri-
bution of a significant amount of cells in the CNS. We hypothe-
sized that a progressive escalation in cell dosage might lead to a
progressively enhanced therapeutic effect. Thus, we initiated a
regimen in which cell dosage was amplified by gradually in-
creasing the number of injections over time. We derived the
NSCs from non-virally generated induced pluripotent stem
cells (IPSCs) that were reprogrammed from skin fibroblasts of
healthy subjects. This cell source is attractive due to availability,
similar pluripotency as embryonic stem cells (ESCs) and no
associated ethical controversy. With this strategy, we achieved
a significant improvement in the disease phenotype, even
when treating early-mid symptomatic animals.
RESULTS
Isolation and characterization of an ALDHhiSSCloVLA41
NSC population from human iPSCs
We used an iPSC line generated in our lab with a non-viral, non-
integrating method and fully characterized its pluripotent fea-
tures (Supplementary Material, Fig. S1). We differentiated
iPSCs into NSCs with a multistage differentiation procedure
described previously for human ESCs and iPSCs (15,18)
(Fig. 1A). This protocol generates.90%PAX6-positive neuro-
epithelial cells. Then,weusedFACSanalysis to isolate a specific
cell fraction based on ALDHhiSSClo properties, as previously
described for murine NSCs (Fig. 1B) (11,13). This fraction
was further selected for the expression of VLA4+ (Fig. 1B
and C). ALDHhiSSCloVLA4+ cells are self-renewing and
multipotent, and they also express neural precursor markers
such as SOX1, SOX2 and nestin (Fig. 1D). Moreover, these
cells can differentiate into the three major neuroectodermal
lineages (Fig. 1D–G); they differentiate into motor neurons
when grown in the presence of retinoic acid (RA) and sonic
hedgehog (SHH) (15) (Supplementary Material, Fig. S2).
Both intrathecally and systemically transplanted
ALDHhiSSCloVLA41 NSCs engraft in the
spinal cord of SOD1G93A mice
To assess the therapeutic potential of ALDHhiSSCloVLA4+
NSCs, we evaluated whether the NSCs reached the CNS follow-
ing intrathecal injection or systemic administration. For these
experiments, we used the SOD1G93A mouse model of ALS
(Figs 2 and 3). ALDHhiSSCloVLA4+ NSCs (1× 106 cells)
were delivered into the CSF by lumbar puncture in SOD1 mice
at 90 days of age, with additional injections at 105 and 120 days
of age (Fig. 2A). For the systemic injection, cells were delivered
beginning at 90 days of age with weekly injections into the tail
vein until the end stage (Fig. 3A). To trace the transplanted cells
in the host spinal cord, we used ALDHhiSSCloVLA4+ cells
expressing green fluorescent protein (GFP). To assess donor cell
distribution and engraftment, the brain and spinal cord were
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collected at 140daysand at the end stage of the disease.Visualiza-
tion of ALDHhiSSCloVLA4+ cells in the spinal cord revealed
single cells in thehost parenchymaandcells distributed inclusters
(intrathecal model: Fig. 2B; systemic model: Fig. 3B). When
ALDHhiSSCloVLA4+ donor cellswere intrathecally or system-
ically administered, they engrafted in both grey and white matter
regionsof themouse spinal cord.Aquantitative analysis ofdonor-
derived cells showed a significantly higher density of donor cells
in the anterior horn, the site of active degeneration. In particular,
the anterior horns in the cervical and lumbar regions had higher
cell densities relative to the thoracic zone (intrathecal model:
Fig. 2C; systemic model: Fig. 3C).
Quantitativemeasurements of donor-derived cells in the spinal
cord showed that an averageof 6.49+0.55cells per section in the
cervical and 6.7+0.41 cells per section in the lumbar spinal cord
werepresent following intrathecal administration(Fig.2C).Asig-
nificant proportion of donor cells maintained an undifferentiated
phenotype, while the rest differentiated into neuronal and glia
cells (Fig. 2D and E, Supplementary Material, Fig. S3). The
vastmajorityofcellsexpressGABA,supportiveofaneuronalpre-
cursor phenotype or of an interneuronal phenotype. Few cells
display a cholinergic phenotype, supported by their positivity
for ChAT. Glial cells are almost all astrocytes, and only a minor
proportion acquired an oligodendrocytic phenotype (,5%) as
quantified in Figure 2.As expected for their ectodermal embryon-
ic layer commitment, NSCs do not differentiated into microglia.
Donor cells also reached thebrain andweredetected in thecortical
and subcortical brain areas (SupplementaryMaterial, Fig. S4).No
adverse effects, including tumour formation, abnormal cell
growth or inflammation, were detected in the recipient animals.
In the animals treated with systemic injections, quantification
of donor-derived cells in the spinal cord revealed the presence of
8.66+ 0.49 cells per section in the cervical and 8.93+ 0.38
cells per section in the lumbar spinal cord (Fig. 3C). We found
Figure 1.Differentiation of iPSCs into NSCs and selection of the ALDHhiSSCloVLA4+ fraction. (A) Scheme of the differentiation protocol of NSCs from iPSCs.
Initially, the iPSCs are positive for OCT4. After detaching from the plate, the iPSCs form aggregates that are cultured for 7 days in neural medium. The differentiated
cells show features of neuroepithelial (NE) rosettes. The primitiveNE cells were positive for PAX6. These cells were then selected by FACS for their ALDHhiSSClo
andVLA4positivity and expanded in vitro. The cellswere culturedwithRAandSHHanddifferentiated intoOLIG2-expressingmotor neurons. They could be further
matured into their neuronal phenotype in thepresenceof neurotrophic factors and reducedconcentrationsof SHHandRA. (B)Representativeflowcytometric analysis
ofALDHactivity andVLA4+ positivity on iPSC-derivedNSCs.NSCswere selected according to forward and side scatter properties.Cells incubatedwithAldefluor
substrate and the specific inhibitor of ALDH (DEAB) were used to establish the baseline fluorescence and to define the ALDHhi region. After sorting, this cell popu-
lation is enriched as shown in the right panel. TheALDHhiSSClo fractionwas further selected by FACS forVLA4 expression (left panel) and seeded in culture. Scale
bar: 70 mm. (C) iPSC cells positive for VLA4 (red; nuclei stained with DAPI, blue signal). (D) Sorted ALDHhiSSCloVLA4+ cells grown at clonal density in NEP
medium form epithelial-like clones positive for NSCmarkers such as SOX1, SOX2 and nestin. Scale bar: 100 mm.After in vitro differentiation, ALDHhiSSClo cells
could give rise to cells of the three neuroectodermal lineages includingGFAP-positive astrocytes (red),O4-positive oligodendrocytes (red) andmotor neurons (ChAT
red, TuJ1, green). Nuclei are counterstainedwithDAPI (blue signal). Scale bar: GFAP, 100 mm;O4, 50 mm; and TuJ1 andChAT, 100 mm. (E) Quantification of cells
positive forNSCmarkers. (F)Quantification of cells showing positive staining for astrocyte and oligodendrocytemarkers after appropriate differentiation. (G)Quan-
tification of cells that are double-positive for motor neuron markers TuJ1 and ChAT.
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Figure 2. iPSC-derived NSCsmigrate and engraft into the spinal cords of SOD1G93Amice after intrathecal and systemic transplantation. (A) Experimental design:
GFP-NSCs (1 × 106 cells) were delivered by intrathecal injection into SOD1G93A mice at 90 days of age, with two additional injections at 105 and 120 days.
(B) Donor GFP+ cells were detected in the spinal cord, particularly in the anterior horns. (C) Quantification of GFP-donor cells in the cervical, thoracic and
lumbar spinal cord. Error bars indicate the SD. (D) Quantification of the phenotype acquired by the donor cells revealed the presence of cells with an undifferentiated
phenotype (nestin), neuronal (NeuN)phenotype andglial cells (GFAP).Error bars indicate theSD. (E)Representative images of cells acquiring aneuronal phenotype,
as indicated by positivity for NeuN (red) and GFP (green). Nuclei are counterstained with DAPI (blue signal). Scale bars: (B) 150 mm and (E) 50 mm.
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Figure 3. iPSC-derived NSCs migrate and engraft into the spinal cords of SOD1G93Amice after intravenous transplantation. (A) Experimental design: GFP-NSC
cells (1 × 106 cells)were deliveredbyweekly intravenous injection intoSOD1G93Amice starting at 90days of age. (B andC)DonorGFP+ cellsweredetected in the
spinal cord, particularly in the anterior horns. (C) Quantification of GFP-donor cells in the cervical, thoracic and lumbar spinal cord. Error bars indicate the SD.
(D) Quantification of the phenotype acquired by the donor cells revealed the presence of cells with an undifferentiated phenotype (nestin), a neuronal (NeuN) pheno-
type and a glial (GFAP) phenotype. Error bars indicate the SD. (E) Representative images of cells acquiring a neuronal phenotype that are positive for NeuN (red) and
GFP (green). Scale bars: (B) 150 mm right, 120 mm left; (E) 50 mm upper panel, 75 mm lower panel.
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IgG deposits from blood vessels in the spinal cord of SOD1mice
but not in wild-type mice (Supplementary Material, Fig. S5).
These data confirmed the weakness of the BBB in SOD1G93A
mice (16,17,19), which allowed transplanted cells to reach the
spinal cord after the systemic injection. The phenotype of the
cells transplanted by intravenous injection was similar to the
intrathecal administration; the engrafted cells maintained an un-
differentiated phenotype or differentiated into neuronal and glia
cells (Fig. 3D andE, SupplementaryMaterial, Fig. S6).With sys-
temic administration, we also detected the presence of donor cells
in the cortical and subcortical brain areas of ALS mice (Supple-
mentary Material, Fig. S7). Neuronal undifferentiated cells sur-
vived and were detectable until the late stage of the disease,
when the animals were sacrificed. No adverse effects were
observed after systemic transplantation.
Cell transplantation improved disease phenotype
and extended survival of ALS animals
We first evaluated whether both intrathecal and systemic deliv-
ery of ALDHhiSSCloVLA4+ cells could ameliorate the pheno-
type and extend survival in SOD1G93A mice (Fig. 4). For the
phenotypic assessment, mice were tested on the rotarod, and
the survival was recorded.
Intrathecal transplantation of ALDHhiSSCloVLA4+ cells
into SOD1G93A mice (n ¼ 24) significantly extended survival
by 10 days compared with vehicle-treated animals (n ¼ 25)
(vehicle, 143+ 6 days mean survival; ALDHhiSSCloVLA4+,
153+ 5 days; x2 ¼ 6.1, P ¼ 0.0135; Fig. 4B). Systemic trans-
plantation of ALDHhiSSCloVLA4+ cells into SOD1G93A
mice (n ¼ 16) also significantly extended survival by 23 days
compared with vehicle-treated animals (n ¼ 24) (vehicle,
148+ 7 days mean survival; ALDHhiSSCloVLA4+, 171+ 6
days;x2 ¼ 11.81,P ¼ 0.0006; Fig. 4D). The survival difference
between the intrathecal and systemic group was statistically
significant (P ¼ 0,0001). The rotarod test was used to assess
neuromuscular function in transplanted and untreated animals.
At 4 weeks after starting transplantation, the cell-treated
animals presented a significant improvement in rotarod perform-
ance relative to untreated (P , 0.001) and fibroblast-treated
animals (P , 0.001) (Fig. 4A and C). Rotarod functional
outcome was similar between the two groups and the difference
is not statistically significant.
To determine whether ALDHhiSSCloVLA4+ transplant-
ation protects against the loss of motor neurons, we quantified
the number of motor neurons in spinal cord sections and
ventral spinal nerve roots. At 140 days of age, motor neuron
loss was significantly reduced by cell transplantation via both
intrathecal and systemic administration. Mice transplanted
with stem cells had 40% more motor neurons than vehicle-
treated SOD1G93A mice (P, 0.001); this increase likely
accounted for the observed functional improvement (Fig. 4E).
Transplanted animals also presented with a preservation of
axonal density in the L4 ventral root, while control mice
showed a substantial reduction in axons compared with wild-
type mice. Quantitative assessment revealed that in both trans-
planted SOD1G93A groups, significantly fewer axons were
lost with untreated SOD1 mice (treated versus untreated P,
0.001). Axons in adult L4 ventral nerve roots were preserved,
showing an increase of 50% with respect to vehicle-treated
animals (P, 0.001) (Fig. 4F).
WedetecteddonorGFPcells in themuscle located in theprox-
imityof the sarcolemmaof themusclefibres inmice transplanted
systemically at 140 days of age. We hypothesized that neuro-
muscular junction (NMJ) preservation may have been involved
in the improved neuromuscular function in the systematically
delivered group (Supplementary Material, Fig. S8).
Changes in growth factor levels and a reduction
in micro- and macrogliosis after cell transplantation
We next investigated the molecular mechanisms that may under-
lie the observed therapeutic effect. Using an enzyme-linked im-
munosorbent assay (ELISA), we determined that iPSC-derived
ALDHhiSSCloVLA4+ NSCs produced a spectrum of neuro-
trophic and neurite outgrowth-promoting factors (Fig. 5)
(14,15). ALDHhiSSCloVLA4+ NSCs secreted significant
amounts of glial cell-derived growth factor (GDNF) (713.8+
69.75 pg/ml; P, 0.001 versus fibroblasts), brain-derived neuro-
trophic factor (BDNF) (469.67+52.76 pg/ml; P, 0.001),
neurotrophin-3 (NT3) (158.46+21.68 pg/ml; P, 0.001) and
transforming growth factor alpha (TGF-a) (123.51+11.42;
P, 0.001) (Fig. 5A–D).
In our neuropathological analysis, the CNS tissues of
SOD1G93A ALS mice showed the presence of a significant in-
flammatory (microglial) reaction thatmayplay an important role
in the disease pathogenesis (1,10). Interestingly, we demon-
strated a significant reduction in macrophage/microglia cell
populations in both lumbar and cervical spinal cord in treated
mice compared with vehicle-treated and untreated SOD1G93A
mice. The number of activated microglia in the ventral horn
was 146.8+ 13.4 per section in vehicle-treated SOD1G93A
mice versus 65.4+ 7.9 in the intrathecally treated SOD1G93A
mice (n ¼ 6 per group/condition; P , 0.001) (Fig. 5F).
Similar results were obtained with systemic injection, with
54.9+ 9.6 microglia per section in the treated SOD1G93A
mice versus 153.4+ 14.9 in vehicle-treated animals (n ¼ 6
per group/condition; P , 0.001) (Fig. 5F).
Astrogliosis also plays an important role in ALS pathogen-
esis, particularly in non-autonomous motor neuron death
(1,10). Staining for the astrocytic marker glial fibrillary acidic
protein (GFAP) suggested diminished astrogliosis in the spinal
cord (particularly in the critical cervical/lumbar regions) of
NSC-engrafted SOD1G93A mice (Fig. 5E). The number of
hypertrophic reactive astrocytes in the ventral horn was
254.9+ 24.6 per section in vehicle-treated SOD1G93A mice
versus 163.9+ 12.4 in intrathecally treated SOD1G93A mice
(n ¼ 6 per group; P, 0.001) (Fig. 5G). In the systemic injec-
tion group, we observed amean of 145.6+ 22.3 GFAP-positive
cells compared with 243.7+ 21.8 in the vehicle-treated group
(n ¼ 6 per group; P, 0.001) (Fig. 5G).
NSCs inhibit ALS astrocyte activation through
TRPV1 receptor activation
Wenext analysed the possiblemolecularmechanisms involved in
the reduction of astrocyte activation/proliferation by NSC trans-
plantation (Fig. 6). In a series of in vitro experiments, we demon-
strated that stimulating mouse astrocytes with factors released
from iPSC-derived NSCs, but not with factors released from
fibroblasts, significantly reduced the viability of SOD1G93A
astrocytes. NSCs reduce astrocytic tumour expansion by
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releasing endovanilloids that activate the vanilloid receptor (tran-
sient receptor potential vanilloid subfamily member-1, TRPV1)
on astrocytic cells (20). Therefore, we investigated whether
similar events occurred during ALS. First, we demonstrated
that astrocytes from the CNS of SOD1 mice express TRPV1
(Fig. 6A). We found that NSCs are toxic for astrocytes when
grown in co-culture (Fig. 6B). We further showed that blocking
TRPV1 with the selective antagonists iodoresiniferatoxin
(I-RTX, 10 nM) or capsazepine (CZP, 1 mM) decreased the cyto-
toxicity ofNSCson astrocytes (Fig. 6C). The toxic effect ofNSCs
on astrocytes was selectively restricted on the SOD1background,
while non-transgenic and ALDHhiSSCloVLA4+ NSC-derived
Figure 4. Transplantation of ALDHhiSSCloVLA4+ NSCs improves neuromuscular function, increases survival and reduces motor neuron and axon loss in ALS
mice. (A andC) Transplantation ofNSCs significantly improvedmotor performance in SOD1mice, as demonstrated by the rotarod test both in the intrathecally trans-
planted group (A) and in systemically injected mice (C) (4 weeks after transplantation, P , 0.001, ANOVA). (B and D) Kaplan–Meier survival curves for mutant
SOD1mice treated intrathecally (B)or systemically (D)withALDHhiSSCloVLA4+NSCsorwithvehicle.Survivalwas significantly extended forNSC-transplanted
mice comparedwith vehicle-treatedmice for both treatment groups (P , 0.05, log-rank test). (E) Themotor neuron count (n ¼ 6 for each group) in the lumbar spinal
cord of NSC-transplanted, vehicle-treated SOD1mice and wild-typemice (data represent the mean+SD of the number of motor neurons per section) at 140 days of
age. The evaluation revealed significantly increased numbers of surviving motor neurons in treated SOD1G93A mice (P, 0.001, ANOVA). (F) Quantification of
axons (data represent the mean+SD) at 140 days of age (n ¼ 6 for each group) demonstrated that transplanted SOD1G93Amice showed a significantly increased
number of axons (P , 0.001, ANOVA).
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astrocytes were not affected (Fig. 6D). Thus, we conclude that
donor NSCs reduce reactive astrocytes in the CNS of SOD1
mice by activating TRPV1.
DISCUSSION
In this study, we found that repeated intrathecal or systemic
injection of a specific NSC subpopulation ameliorates the ALS
disease phenotype in a mouse model. These results, combined
with the minimally invasive nature of the delivery method,
support the rationale and utility of this approach for patients
with ALS. The beneficial effects of engrafted ALDHhiSS
CloVLA4+ NSCs include improved neuromuscular function
and survival, neuroprotection and positive host-environment
modifications at the neuropathological level.
Stemcell transplantation isgaining increased interestasa thera-
peutic strategy because its multifaceted impact can counteract a
Figure 5. NSCs produce neurotrophins and reduce micro- and macrogliosis in SOD1G93A mice. The amounts of (A) GDNF, (B) BDNF, (C) NT3 and (D) TGF-a
secreted by the NSCs were determined by ELISA, which demonstrated a significant production of these neuroprotective substances with respect to fibroblasts.
(E) Expression ofGFAP (red)was reduced in the spinal cord of transplanted SOD1mice. Nuclei are stainedwithDAPI (blue). Scale bar: 70 mm.NSC transplantation
significantly reduced the presence of microglial cells (F) and astrocytes (G) in the spinal cord of intrathecally and systemically injected mice (data represent the
mean+SD, ∗significant, P , 0.001, ANOVA).
Human Molecular Genetics, 2014, Vol. 23, No. 2 349
 by guest on D
ecem
ber 4, 2015
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
number of processes that underlie disease pathogenesis. Molecu-
lar and pharmacological strategies that focus on a single or few
targets have been minimally successful in ALS clinical trials,
likely because they address only one aspect of this complex neu-
rodegenerative disease. In contrast, several experimental
approaches of NSC transplantation have produced positive
effects on motor neuron disease in animal models (9–15).
Among the potential cell sources, our population of
ALDHhiSSCloVLA4+ stem cells/precursors is an attractive
choice for both reproducibility and the lack of controversy
regarding their collection; they can be derived from autologous
or donor fibroblasts, reprogrammed into iPSCs, and grown
in vitro. In addition, they can migrate from the CSF or blood to
the spinal cord parenchyma. This property allows non-invasive
transplantation, which is important for clinical translation to
patients. Furthermore, these cells present robust survival in the
host CNS and do not trigger side effects such as tumours or ab-
normal cell growth. Indeed, we showed that the donor cells ap-
propriately migrate and localize throughout the entire spinal
cord, particularly in the specific areas that are affected by the
disease: the cervical/lumbar enlargement, the anterior horns
and the areas around endogenous motor neurons. The donor
cells were also located in cortical brain areas, thus positively
influencing the upper motor neurons. Of importance, donor
ALDHhiSSCloVLA4+ cells maintained their stem cell/
precursor phenotype or differentiated into neuronal and glial
cells, changing the spectrum of cell phenotypes in the host tissue
microenvironment.
Regarding themechanismsof cellmigration from theCSFand
blood toward the parenchyma, the neuronal death that occurs in
ALS could be a signal that promotes NSC attraction into the
CNS. Indeed, the presence of an altered BBB in ALS mice and
patients can promote cell migration (17). VLA4 is a surface
protein that mediates transendothelial migration. It is expressed
on some haematopoietic cell fractions, in particular on T lym-
phocytes, and mediates their ability to cross the BBB (21).
A humanizedmonoclonal antibody against VLA4, natalizumab,
is used to treat multiple sclerosis because it blocks the migration
of T lymphocytes into the CNS (21). In contrast, the presence of
VLA4 onNSCs gives them the ability to cross the BBB, particu-
larly in the presence of inflammation or weakened BBB, as
demonstrated in humans and animal models of ALS (16,17).
ALDHhiSSCloVLA4+ NSC-treated SOD1 mice presented
an amelioration of the motor neuron phenotype, demonstrated
by neuromuscular function tests and increased survival. Trans-
plantation of ALDHhiSSCloVLA4+ cells significantly pro-
longed survival compared with vehicle-treated animals. The
increased survival time, although limited, is relevant considering
previous reports ofNSC transplantation in rodentmodels ofALS
that also showed a transient improvement in motor performance
and amodest increase in survival (22). Recently, the Teng group
reported a remarkable survival increase of 200 days in 40%or up
to a full year in 20%of SOD1 animals injectedwithNSCs at four
sites of the spinal cord during the presymptomatic stage of
disease (10). However, the remaining 40% of mice showed a
very mild increase in survival, demonstrating a large variability
in outcome with unknown cause. The transplantation method
used byTeng et al. (10) required a direct intraparenchymal injec-
tion at multiple sites. This procedure is more invasive than the
intrathecal and systemic injections that were used in this study.
One possibility for the difference in benefit obtained with the
more invasive cell therapy by Teng et al. (10) can lie in the
number of NSCs that successfully engrafted the parenchyma.
However, a direct comparison cannot be performed because
the authors do not present a quantitative analysis of engrafted
donor cell number, even if we can assume indirectly from
other data, such as images of the treated mouse spinal cord,
that the number of cells was higher than what we achieved in
our experiments. Indeed, both our group and Teng’s group
observed a positive correlation between the number of engrafted
cells and the positive outcome.
Figure 6. NSC-mediated astrocyte suppression by activating endovanilloid
receptorTRPV1. (A) SOD1G93Aastrocytes (GFAP, green) are immunopositive
for TRPV1 (red). A single cell is magnified on the left, and pixels with
co-localized staining in a single optical section are shown. Scale bars: 40 mm
on the left, 10 mm in the higher magnification panel. (B) The viability of
SOD1G93A astrocytes is reduced after stimulation with NSC-conditioned
medium (NSC) but not after stimulation with non-conditioned medium (Ctrl).
(C) The NSC-induced cytotoxicity of astrocytes was blocked by the TRPV1 se-
lective antagonists I-RTX and CZP. (D) The toxic effect of NSCs on astrocytes
was present on SOD1 astrocytes, while non-transgenic mouse astrocytes and
on ALDHhiSSCloVLA4+ NSC-derived astrocytes were not significantly
affected. All data are mean+SD. ∗P , 0.05, ∗∗P , 0.005 by Student’s t-test.
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The strategy of repeated delivery of the cells allowed achiev-
ing a widespread distribution of a significant amount of cells in
the CNS. We hypothesized that also in clinical translation, the
therapeutic effect would be proportional to the number of
engrafted cells that can be achieved with multiple injections.
Regarding the risks of raising an immunoresponsewith this strat-
egy, differentiated cells derived from iPSCs, including NSCs,
present a low immunogenic profile (23,24). Moreover, the
CNS is a low responding immunological site. In any case, immu-
noresponse stimulated by repeated injection ofNSCs can be con-
trolled by immunosuppressant agents, as we achieved here in
mice; no signs of immunorejection were observed. VLA4 is a
physiological antigen expressed in human cells, so it will not ini-
tiate an immune response in humans.
We demonstrated an increased therapeutic effect when the
cells were administered by systemic injection compared with
intrathecal injection.Wehypothesize that,with a systemic injec-
tion, donor NSCs can exert a positive role both locally and per-
ipherally. After entering the CNS via cell adhesion molecules
(such as VLA4) and chemokine receptors, systemically injected
NSCs accumulate in perivascular CNS areas and in the areas of
active degeneration. As a consequence, transplanted NSCs
survive and promote neuroprotection by releasing neurotrophic
factors in situ. There is further evidence suggesting a peripheral
immunomodulatory effect of the NSCs (25). Systemically
injected NSCs also enter peripheral organs (e.g. draining
lymph nodes and spleen), where they accumulate at the bound-
aries of blood vessels. Here, they interact closely with lympho-
cytes and professional antigen-presenting cells, impairing their
maturation and functional activation (25). Indeed, we hypothe-
size a peripheral effect of NSCs, which secrete neuroprotective
factors at the skeletal muscle level, on the maintenance of
NMJ integrity; however, experimental demonstration is still
needed. Accumulating evidence suggests that clinical ALS is
possibly a multi-organ disease. Although motor neurons are se-
lectively affected in ALS, the possibility that ALSmight be part
of a systemic disease in whichmotor neurons are especially vul-
nerable has been hypothesized. In fact, a number of well-
established abnormalities in ALS occur in the immune system,
skin, skeletal muscle tissue and lipid metabolism (see for
review26). Moreover, we have to consider that the systemic
delivery relies on multiple injections respect to the intrathecal
delivery over the same period of time and the maintenance of
the NSCs presence may have been more continuous for the sys-
temic route than for the other one, even if at 140 days and at the
end stage of the disease the difference in NSC integration
between the two routes of delivery was only slightly different.
We hypothesize that the therapeutic effect of ALDHhiS
SCloVLA4+ cells in our study relies on multiple mechanisms
that include both neuroprotection and reduction of macro- and
microglia. NSCs constitutively secrete various neurotrophic
and neuroprotective molecules that can exert a synergistic
effect superior to the administration of a single molecule.
These factors seem to protect host motor neurons and functional
neuromuscular units, reduce macrophage/microglial infiltration
and decrease endogenous astrogliosis (10,22). In particular, we
observed an increase in the production of GDNF, which can
exert a direct neuroprotective effect on endogenous cells. The
modest effects of neurotrophic factor treatment on lifespan in
previous clinical studies of ALS suggest several explanations
including that they are physiologically effective but limited by
pharmacokinetic constraints (27).
Indeed, NSCs constitutively secrete more than one neuro-
trophic and neuroprotective factor. We also demonstrated a re-
duction in the levels of activated macro- and microglia after
cell transplantation, suggesting a potential anti-inflammatory
effect of ALDHhiSSCloVLA4+ cells. Even if wild-type astro-
cytes can exert a positive effect on motor neurons, we and
others (10) have demonstrated that the reduction in astrocytosis
plays a part in the therapeutic effect achieved by cell transplant-
ation. Therefore, a reduction in astrocytes can be considered a
shift of the ALS neuropathological features towards a physio-
logicalwild-type pattern.Our results suggest a novelmechanism
in which NSCs reduce macrogliosis by activating the vanilloid
receptor. Thus,NSCs not only provide cells of the three neuroec-
todermal lineages to the host cell environmental, but they can
also influence the behaviour of endogenous cells. Identifying
the full range of variables underlying the success of cell trans-
plantation is essential for confirming the reproducibility of the
therapeutic response for clinical application.
In the present work, we described a feasible and efficient
protocol for the generation ofNSCcells from iPSCs that are scal-
able for producing highly pure populations of functional iPSC-
derived NSCs sufficient for clinical translation. Converting the
cell dose used in a mouse to a dose based on surface area (28),
we can estimate that for humans we would have to transplant
an approximate dose of 1 × 108 cells/m2 that for a man of
60 kg (with a body surface area of 1.6 m2) would be 1.6 × 108.
Given their indefinite self-renewal, with a doubling time
between 24 and 48 h, human iPSCs have the potential to yield
an unlimited supply of NSCs.
Our results provide evidence that ALDHhiSSCloVLA4+
NSCs derived from iPSCs may represent an effective approach
for the treatment of ALS. We demonstrated that the beneficial
effects observed after stem cell transplantation arise from mul-
tiple events that counteract multiple aspects of the disease; this
feature is crucial for multifaceted disease such as ALS. A com-
bination of therapeutic approaches that target different patho-
genic mechanisms of the disorder, including pharmacology,
molecular therapy and cell transplantation, will increase the
chances of a clinically successful therapy for ALS.
MATERIALS ANDMETHODS
Generation of iPSCs
Human skin fibroblasts were reprogrammed as previously
described (15) using oriP/EBNA1-based episomal vectors en-
coding the human genes OCT4, SOX2, NANOG, LIN28,
c-Myc and KLF4. After nucleofection, fibroblasts were plated
onto 3 × 10 cm dishes covered with Matrigel (BD Biosciences)
in fibroblast culture medium, which was changed every other
day. Four days after transfection, the fibroblast culture
medium was replaced with human ESC culture medium
(mTeSR, Stemcell Technologies Inc.) for 8–10 days. At day
18 after transfection, the first colonies with an iPSC-like morph-
ology could be identified.We then picked the iPSC colonies that
were morphologically similar to ESCs for further analysis and
expansion, as previously described (15).
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Differentiation of iPSCs and selection of the
ALDHhiSSCloVLA41 fraction
We differentiated iPSCs into neuroepithelial cells using a previ-
ously described differentiation protocol (15). iPSCs were plated
in neuronal medium composed of Dulbecco’s modified Eagle’s
medium/F12 (Gibco, Invitrogen). The mediumwas supplemen-
ted with MEM non-essential amino acids solution, N2 and
heparin (2 mg/ml; Sigma-Aldrich) to induce the neuroepithelial
commitment.Cellswere then selected byFACS for theirALDH-
hiSSClo properties, as previously described (11,13). The iso-
lated cells were further selected by FACS for their VLA4
positivity (anti-human VLA4, BD) using an appropriate nega-
tive control with cells labelled only with the same isotypic Ig.
For cell expansionandclonal culture,ALDHhiSSCloVLA4+
cellswere plated in a previously described growthmedium (NEP
medium) containing FGF with or without EGF (13). Differenti-
ation of cultured ALDHhiSSCloVLA4+ cells was induced by
plating on poly-lysine/laminin-coated dishes (poly-lysine at
20 mg/ml in DPBS; Sigma) and reducing the FGF concentration
with the addition of RA (1 mM). To induce the motor neuronal
phenotype, NSCs were exposed to additional RA (0.1 mM;
Sigma-Aldrich) for neural caudalization. After 7 days, we col-
lected the posteriorized neuroectodermal cells and suspended
them for a week in the same medium with RA (0.1 mM) and
SHH (100–200 ng/ml; R&D Systems Inc.). On day 24, we
added the growth factors BDNF, GDNF and insulin-like
growth factor-1 (10 ng/ml each; PeproTech).
Immunocytochemistry of iPSCs and their derivatives
Cellswere fixed in 4%paraformaldehyde (PFA) for 10 min, per-
meabilized with 0.5% Tween-20 in phosphate-buffered saline
(PBS) and exposed to 0.1% Tween-20 with 10% horse serum.
We incubated the cells with primary antibodies overnight and
with secondary antibodies for 1 h (Alexa Fluor, Invitrogen).
Weused the following primary antibodies: SSEA-3 (1:100,Che-
micon), SSEA-4 (1:500, Chemicon), TRA1-60 (1:500, Chemi-
con), TRA1-81 (1:500, Chemicon), Pax6 (1:200, Millipore),
nestin (1:200, Millipore), Sox1 (1:1000, R&D,), SOX2
(1:1000, Millipore), TuJ1 (1:200, Millipore), GFAP (1:300,
Sigma), Islet1/2 (1:200, Millipore), HB9 (1:200 Millipore),
ChAT (1:200, Millipore), MAP2 (mouse monoclonal, 1:100;
Sigma), O4 (10–20 mg/ml, Millipore) and Musashi (1:200,
Novus Biological). The HB9::GFP gene reporter was used to
identify motor neuron cells, as previously described (29). For
all imaging, we used a confocal LEICA LCS2 microscope.
Animal models
We used transgenic mice of the strain B6.Cg-Tg(SOD1-
G93A)1Gur/J, which carries a high copy number of the mutant
human SOD1 allele containing aGly93Ala (G93A) substitution.
Progeny for experimental analyses was obtained by breeding
SOD1G93A transgenics with C57BL/6 wild-type mice. Trans-
genicmice were identified by polymerase chain reaction, as pre-
viously described (14). All animal experiments were approved
by the University of Milan and Italian Ministry of Health
review boards and are in compliance with the USNational Insti-
tutes of Health guidelines (14).
Cell transplantation
Ninety-day-old transgenic SOD1G93A mice were transplanted
with ALDHhiSSCloVLA4+ cells (1× 106 cells) or vehicle
only (saline) by intrathecal injection (5 ml) (three injections) or
by injection through the tail vein (100 ml, weekly injections)
(14). These cells were also genetically engineered to express
GFP driven by the cytomegalovirus promoter (15). The cells
were harvested and prepared for transplantation as previously
described (15). The intrathecal group included 24 mice (12
males) for transplantation and 25 mice (12 males) in the vehicle
control group. The intravenous group included 16 transplantation
mice (8 males) and the vehicle group of 24 mice (12 males). The
animals were evaluated up to the end stage for rotarod perform-
ance, survival andhistological evaluationofdonorcellphenotype.
The study was designed such that littermates were distributed
equally among the transplanted and non-transplanted groups.
Three groups of animals (each composed of six mice per time
point per condition)were euthanized at 140 days of age for histo-
logical analysis, quantification of motor neurons and axons and
growth factor evaluation via ELISA.
Tissue analysis
Animalswereeuthanized,perfusedandfixedwith4%PFAinPBS
(pH 7.4). The spinal cord was isolated, immersed in PFA for 1 h
and then soaked overnight in 20% sucrose in PBS (pH 7.4). The
fixed tissue was frozen in Tissue Tek OCT compound (Sakura)
with liquid nitrogen. Tibialis anterior muscles were removed
prior flash-frozen in supercooled isopentane. The tissues were
cryosectioned and mounted on gelatinized glass slides. Every
tenth 20 mm section was collected. All sections were blocked
with 1% fetal calf serum in PBS and permeabilized with 0.25%
TritonX-100.Sectionswereprocessed formultiplemarkers tode-
termine the cellular phenotype of GFP-labelled cells. Primary
antibodies were added overnight at 48C at dilutions of 1:200 for
NeuN (mouse monoclonal antibody, Chemicon), 1:200 for
nestin (mouse monoclonal, Chemicon) and 1:200 for GFAP
(mouse monoclonal Cy3 conjugate, Sigma) and laminin (rabbit
polyclonal, 1: 500, Sigma-Aldrich).
Mouse and rabbit secondary antibodies conjugated with FITC,
RPE,CY3or biotin (1:200; Jackson ImmunoResearchLaborator-
ies, Inc., andDako)wereapplied for1hat roomtemperaturewhen
unconjugated primary antibodies were used. Anti-GFP antibody
rabbit serum Alexa 488 (1:400 dilution; Molecular Probes) was
used to reveal GFP expression. Co-expression of GFP and tissue-
specific markers was evaluated by conventional fluorescence mi-
croscopy (Zeiss Axiophot) and laser confocal scanning micros-
copy (Leica TCS SP2 AOBS). Optical dissectors and random
sampling were used to obtain an unbiased stereological estimate
of the number of GFP-positive cells. To quantify donor cells,
we used every tenth coronal section (20 mm) throughout the
entire spinal cord (amean of 25 sections per animal). The numer-
ical density of cells was estimated using the optical dissector
method (14). Optical dissectors sized 100 × 70 × 14 mm were
randomly sampled, and the number of positive cells in each dis-
sector was quantified. The density was calculated by dividing
the total number of donor cells by the total volume of optical dis-
sectors. The total volume of tissue per specimen (Vcord) contain-
ing donor cells was calculated using the Cavalieri method (14).
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This total volume of tissue, multiplied by the number of donor
cells per cubic micrometre (Nv), yielded the total number of
donor cells per specimen (n ¼ Nv× Vcord) (14).
Assessment of motor function and survival
Vehicle- and cell-injected SOD1G93A mice were monitored
daily following transplantation for clinical signs of disease
onset. Motor performance was assessed using an accelerating
rotarod device (4–40 rpm Rota-Rod 7650; Ugo Basile,
Comerio, Italy). The length of time that the mice remained on
the rotarod was recorded. The investigators performing the be-
havioural assessment were blind to the treatment. Mortality
was scored as the age at which the mouse was unable to right
itself within 30 s when placed on its back, as previously
described (14).
Motor neuron and axon count
Paraffin serial sections (12.5 mm) of lumbar spinal cord were
Nissl-stained toquantifymotorneuronnumbers via lightmicros-
copy, as previously described (14). For the axon count, the tissue
was dissected, immersed in 2.5% glutaraldehyde overnight and
post-fixed in 2% osmium tetroxide. Samples were then dehy-
drated in ethanol and embedded in Epon resin. Semi-thin trans-
verse sections (1 mm)were stained with toluidine blue. L4 roots
were examined for axon counting on an optic microscope.
Enzyme-linked immunosorbent assay
BDNF, GDNF, NT3 and TGF-a secretion by NSCs was mea-
suredbyELISAaspreviously described (14). The datawere ana-
lysed using Student’s t-tests.
Analysis of macro- and microgliosis
Histological analysis for quantification of microglia and astro-
cytes was performed as described (10).
TRPV1 evaluation and cytotoxicity assay
Detection of the TRPV1 receptor, conditioned medium experi-
ments and the cytotoxicity assay were performed as previously
described (20).
Statistical analysis
Kaplan–Meier survival analysis and the log-rank test were used
for survival comparisons. The rotarod test data were analysed
usinganANOVAfollowedbyaTukeypost hoc analysis formul-
tiple comparisons. The numbers of motor neurons and axons
were statistically evaluated by one-way ANOVA followed by
a Tukey post hoc analysis. ELISA results were analysed using
Student’s t-tests. In culture assays, differences between mean
values were analysed using a two-tailed Student’s t-test.
WeusedStatsDirect forWindows (version 2.6.4) for all statistical
analyses, rejecting the null hypothesis at the 0.05 level.
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